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IN a previous paper the writer (Cohen, 1949) proposed a biological dosage
unit, the "roentgen equivalent clinical" (rec) based on an empirical formula
D = E.a.Tn.L-q, relating the physical dose in roentgens (D) to the biological
dose in rec (E), taking into account the relative biological efficiency of radiation
of various qualities (a), the over-all time in days (T), and the field size in deci-
metres (L). The physical and biological doses could be equated when the
specific ion-density is minimal (a = 1), the treatment is completed in 1 day
(T = 1), and the field diameter is 1 dm. (L = 1). The rec was then defined as
the biological effect of 1 r of y-rays delivered through a 1 decimetre diameter
fieldin 1 day. Theparameters n and qwere assumed tobe constants, independent
of the other factors, and their magnitudes were tentatively estimated. For the
skin erythema reaction E = 1000 rec, and n q = 0.33; while for the epi-
dermoid cancer lethal effect E = 3200 rec, n = 022 and q = 0. Since then
many hundreds of cases were treated with doses calculated on this basis, and of
these only a few developed reactions which differed remarkably from expectation.
However, the scheme is based on assumptions and simplifications, the validity
of which is by no means obvious.
The formula assumes that the exponents n and q are independent of the
quality of the radiation, and it makes no allowance for the variation among
individual patients. It becomes necessary, therefore, to determine the extent
to which n and q may be influenced by varying the quality of the radiation;
and to estimate, as far as possible, the magnitude of the individual variability.
The tumour dosage data, moreover, were obtained from observations on treated
cases published by several authors, among whom the estimated curative dose,
and the proportion of cures obtained with this dose, differed very widely. The
analysis of this data, therefore, gave rather crude average values, from which
more orless deviation is to be expected inindividual cases. Inorder to determine
the dose required to cure the growth in all or most treated cases (say 99 per cent),
it becomes necessary to estimate an additional parameter, the variance of the
dosage. For this purpose the response to treatment of250 suitable cases selected
from the follow-up clinic of the Radiation Therapy Department, Johannesburg
General Hospital, during 1950, was statistically analysed.DOSAGE FACTORS IN RADIOTHERAPY
Observations on Skin Reactions.
In the treatment of neoplastic conditions in the Department six different
qualities of radiation are in use:
(a) Radium y-rays; i mm. Pt filtration.
(b) 220 kVp x-rays; 1 mm. Cu filter; HVL 1.5 mm. Cu.
(c) 180 kV(cp) x-rays; 2 mm. Cu filter; HVL 0.9 mm. Cu.
(d) 140 kVp x-rays; i mm. Cu filter; HVL 0.4 mm. Cu.
(e) 140 kVp x-rays; 2 mm. A1 filter; HVL 0.2 mm. Cu.
(f) 60 kV Chaoul unit; HVL 0-16 mm. Cu.
A total of 150 consecutive cases (25 in each qualitative group), in which the skin
dose could be accurately computed were selected for analysis. In order to
eliminate uncertainties due to exit doses and the effect of contiguous fields, only
those cases treated by a single field were used. In each case note was taken of
the skin dose received (D), the over-all time (T), the field diameter (L), and an
estimate of the biological dose (E). D was taken as the maximum surface dose
at the centre ofthetreatedfield; T is the totaltreatment timein days irrespective
of the manner of fractionation, though in the majority of cases treatment was
daily for five days a week; L, in the case of square or circular fields, is the
diameter in decimetres, while with irregular fields the equivalent diameter of a
circle having the same ratio of area: perimeter is taken, so that L = --x Area Perimeter'
and E could be estimated with a fair degree of precision from the intensity of
the observed skin erythema.
Early experiments had shown a rough correlation between the dose delivered
and the observed reaction. It had been noted (Sievert, 1947) that ifthe threshold
erythema dose (1° E) were determined, then delivery of twice this dose produced
a dry desquamative reaction (2° E), three times this quantity gave a moist
epidermitis (3° E), and four erythema doses caused necrosis. In our series of
cases the reactions were classified in these four categories, and further subdivided
into weak, medium or strong reactions in each major category, thus giving
12 distinct gradations of response. It was considered that the four degrees of
reaction correspond to biological doses of 1000, 2000, 3000 and 4000 rec respec-
tively, and the intermediate gradations were evaluated by subtracting 300 rec
for weak, and adding 300 rec for strong reactions in each category. For example,
a strong dry desquamative reaction would be classified as E = 2300 rec. In this
way a quantitative value can be assigned to any observed intensity of skin
erythema in steps of 300 units. Although subjective judgment must enter into
this type of assessment, the error is unlikely to be greater than one step, that is
about 30 per cent for first-degree reactions, and less than 10 per cent for the
more intense reactions.
The dose which would produce a standard erythema in each case, under the
conditions of treatment, is given by the ratio of the physical dose (D) to the
observed biological dose (E). According to our formula, this ratio, designated
(R) in Table I, should, within the limits of error and variation, equal a.Tn.L-q.
It then becomes possible to estimate a, n and q simultaneously by fitting the data,
grouped according to quality, to the line
log R =log a+ n logT-q log L
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-aDOSAGE FACTORS IN RADIOTHERAPY
by the method of least squares as illustrated in Table I. (For practical reasons
only a small part of the original table is reproduced.)
FIG. 1.-Scatter diagrams and regression lines illustrating relationship of dose, reaction, time
and area for three different qualities of radiation. Broken lines delimit the 95 per cent
confidence belt.
The same procedure was applied to each ofthe six qualitativegroups, estimating
in each case the values of a, n and q, and their confidence limits. Preliminary
results showed that whereas a varied considerably from one quality to another,
showing a definite decrease with diminishing half-value layer, n and q appeared
to range about 0.3 without any special trend related to quality, and within each
group n and q were sufficiently close, well within the limits of observational
error, to warrant the assumption that for practical purposes n = q.
The postulate that n = q simplifies the iso-effect formula to - = a ,
which has many important implications. Firstly it lends theoretical support to
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the hypothesis of a "diffusible substance" (Grynkraut and Sitkowski, 1936;
Jolles, 1950), for diminishing the treated field by a given factor, or increasing
the time interval by the same factor, would allow the same proportion of the
"substance" to diffuse across the surface bounding the treated volume. Trans-
lated into practical terms, the relationship of time and area can be expressed in
the form of an empirical law: In order to maintain a constant skin reaction to
a given dose ofradiation, any change in the diameter of the treated field requires
a proportional change in the over-all treatment time. For example, if a field
10cm. in diameter can just tolerate 6000 r in 28 days, then a field 21 cm.in
diameter could tolerate 6000 r in 7 days. Further, beingtwo-dimensional, it is
possible to test the formula visually by fitting the observed points graphically
to the regression lines, as illustrated in Fig. 1. Finally, estimation by the method
of least squares of two parameters rather than three permits a considerably
greater precision in our estimates of a and n (Table II).
The standard deviation (s) of the logarithm of the dosage estimates can be
computed in the usual way. In 95 per cent of cases log Rlies within thelimits
ofour estimated valueplus or minus 2s. It follows that the equivalent confidence
limits for R are given by its estimated valuemultiplied or divided by a factor f2,
where f is the antilog of s (f2 = 1025). It is proposed (in the absence of any
other accepted nomenclature) to call f2 the "uncertainty factor ".
The final estimates for the three relevant parameters in each of the six quali-
tative groups are given in Table II.
TABLE II. Erythema
Quality of radiation. "a "* "n"* "f2."
range
(95% cases).
Radium; i mm.Ptfilter . 105 (-024) . 0.28 -(+.034) . 121 . 870-1260r
220kV; HVL1-5mm.Cu . 0 76(i-030) . 0 29(+ 028) . 1-28 . 600-960r
180 kV; HVL 0*9 mm.Cu . 0 66( 020) . 031( 022) . 23 . 540-810 r
140 kV; HVL 0*4mm.Cu . 052( 012) . 032( 021) . 121 . 420-630r
140kV; HVL02mm.Cu . 0.54(-015) . 0 33(+.024) . 125 . 430-680r
Chaoul; HVL0.16mm.Cu . 049( 025) . 035(047) . 135 . 370-660r
* The limits shown are, in each case, standard errors ofthe estimated parameters.
It will be noted that the six radiation qualities are arranged from above
downward in order of diminishing energy. Inspection of column"a", repre-
senting the mean standard erythema dose, shows that this dose diminishes (or
biological efficacy increases) with diminishing half-value layer. Computation
of the significance of the differences between adjacent qualitative groups shows
that the difference in the biological efficacy of radium compared to 200 kV
roentgen rays is highly significant (p < -001), and the ratio of the two (1 : 0-7)
is in excellent agreement with other estimates (MacComb and Quimby, 1937;
Quastler and Clark, 1945; Sugiura, 1939). The difference between the 220 kV
and 180 kV ranges isstatistically significant (p 0-01), but of minor importance
clinically, so that for practical purposes the two high-voltage qualities may be
grouped together taking a as 0-7. The difference between 180 kV and 140 kV is
again highly significant (p<0.001), while the three groups in the superficial
therapy range do not differ significantly from one another (p = 0-3), so that for
clinical purposes they may be grouped about a 05. There are thus three
clinically distinct quality factors: 1.0 for radium y-rays; 0.7 for the 200 kV
range; and0.5 for superficial therapy.
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It should be noted that the quality factorforradium applies to surface moulds,
implants and intracavitary treatments; it is probable, however, that with
teleradium therapy the value obtaining at greater depths may be appreciably
altered on account of the softening of y-rays by scattering within the tissues.
In the case of Chaoul radiation the value of a = 0.49 is larger than the writer's
previous estimate (Cohen, 1949) of a = 0.3 for low voltage radiation; this may
be partly due to the high inherent filtration (0.2 mm. Ni), and possibly also to the
average surface dose being somewhat lower than the nominal dose. The general
validity, however, of the three quality factors given above, is graphically illus-
trated by the scatter diagrams and regression lines in Fig. 1.
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FIG. 2.-Relationship between threshold erythema dose and half-value layer for a wide range
of radiant energy.
Values for n range from 0.28 to 0.35 and tend to increase as the energy ofthe
radiation is diminished. The differences between these values, even that between
the smallest and greatest ofthem, are not significant (p = 0-25); but the constant
trend through the whole series of five comparisons is probably not fortuitous
(p 2-5 = 0.03). Although it would be of theoretical interest to confirm this
dependence of the time-area factor on the quality of the radiation, especially as
a contrary trend has recently been detected in another experiment (Quastler,
1950, personal communication), it is of little clinical importance, and there is no
reason to depart from the convenient figure n- 0.33 originally assigned.
13
185
. ,^A
IL. COHEN
The uncertainty factor ofthe dosage estimates (f2, actually the antilog oftwice
the standard deviation of log R) ranges from 1.21 to 1.35. This implies that in
95 per cent of all treated cases the reaction is unlikely to differ from expectation
by more than about 30 per cent, which, considering our crudely subjective
estimates of the reactions, is not unreasonable. There are few published data on
the variability of human tissues in their response to radiation with which to
compare our estimates. However, Helmke (1949) accurately measured the
minimum erythema doses for 93 cases treated experimentally, and obtained
data which approximate closely to a lognormal distribution with a mean of
309 r and a standard deviation of 35 r. The uncertainty factor, being 1.22, is in
good agreement with our findings.
The curve in Fig. 2 illustrates the variation in biological efficacy with half-
value layer, and shows the agreement between our estimates and similar data
derived in a different manner by MacComb and Quimby (1937) and by MacKee
andCipollaro (1940). Each point represents the median erythema dose (a X 1000)
estimated from Table II, the vertical lines delimit the 95 per cent confidence
range, and the lettering refers to data by the authors quoted.
In comparing these results with other published data, it is necessary to note
inevitable differences in the definition of the erythema dose. From the method
we have used the standard erythema dose is that which, delivered to a 10 cm.
field in one sitting, produces a "moderate " erythema in 50 per cent of the
treated cases. With the same dose, however, some slight reddening would be
visible in considerably more than half (probably 90 per cent) of the treated cases.
Since this type of " barely perceptible reaction" is a convenient and objective
end-point much favoured in erythema studies, there is obviously need for care in
comparing such results. It is also necessary to distinguish the transient reddening
(Fruiherythems) appearing within 24 hours of the delivery of quite small doses
(Helmke, 1949) from the main reaction (Haupterythems), which reaches its
maximum about three weeks after treatment.
For example, the threshold erythema dose (TED) is defined (MacComb and
Quimby, 1937) as that quantity of radiation giving a faint reddening of the skin,
visible in two to four weeks, in 80 per cent of treated cases. It would, therefore,
differ little from our standard erythema; hence the fair agreement between our
results and the threshold erythema data in Fig. 2.
On the other hand in Tod's (1950) experiment, the median erythema dose
for a 3 cm. diameter field treated at 140 kV with 2 mm. A1 filtration (practically
identical to our group "e ") was only 275 r, the reactions being observed during
the first day. This "Friiherythems" is obviously not in agreement with our
results or with the figures of MacComb and Quimby (1937); but examination
of the same experimental data shows that their actual TED, for which 80 per
cent ofreactions remain visible after one month, is over 500 r (a very satisfactory
agreement). The importance of basing comparative erythema studies on the
true "Haupterythems," visible in the third week after treatment, is emphasized.
Curability of Epithelioma.
From an analysis of published data on the optimum dosage for squamous
epithelioma in various situations, the (biological) curative dose appeared to
range from 2500 rec to 4000 rec with an average value of 3250 (Cohen, 1949).
Similarly, the recovery exponent (n) was estimated, largely on the basis of Strand-
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qvist's (1944) observations, as equal to 0.22. It was felt, however, that these
important constants could be evaluated within closer limits by an analysis of the
results of treated cases in which the tumour dose, the over-all time, and the
relative biological efficacy of the radiation used, were all precisely known.
For this purpose 100 cases ofepidermoid cancer in various sites were tabulated
and the results analysed statistically. It was necessary to select cases in which
not only was the minimum tumour dose known with certainty, but a sufficient
follow-up was obtained to enable one to decide whether the lesion had in fact been
cured. The customary five-year-cure policy could notbeapplied since estimates of
depth-doses from treatment records prior to 1945 are not sufficiently accurate
for our purpose. It was decided instead to use, as a standard criterion, freedom
from perceptible recrudescence for not less than three years. The records of
100 suitable cases treated between 1946 and 1948, and followed with periodic
examinations through 1950, were abstracted and the data collected in Table III.
The cases are arranged in order of increasing biological dosage (rec).
The dosage data shown are the true mimimum tumour doses, and differed,
especially with superficial therapy, from the nominally given doses. In the case
of very superficial tumours treated with lightly filtered radiation the significant
point was taken to be 5 mm. below the edge of the treated field. With 2 mm. A1
filter this point receives about 85 per cent ofthe given dose; and with the Chaoul
apparatus, only 67 per cent. With deeper growths treated at higher voltages,
standard depth-dose tables were used to assess the tumour dose; while with
radium applicators and implants dosage was calculated on the Paterson-Parker
system.
Since various qualities of radiation were used, it was necessary to correct
the dosage by a factor (RBE) which, taking that for y-rays as unity, becomes 0.5 for superficial therapy, and0.7 for the 200 kV range (TableII). In the case
of deep-seated tumours treated with 200 kV radiation, the half-value layer (and
hence the RBE) in the tissues differs from that of the incident beam on account
of the increase in the average wave-length brought about by the Compton recoil
process. This effect is the more marked the harder the incident radiation. From
data by Stenstrom and Marvin (1946) it appears the HVLinthe depths approaches 0-7 mm. Cu, irrespective of the quality of the incident ray. This corresponds
(Fig. 2) to an RBE of0.6.
The biological dosage (rec) was taken as equal to Dose/(RBE X Tn), where
n = 0-25 (as will be explained below a value of 0-25 gave the smallest variance,
and is consequently considered the most accurate estimate). The column of
results describes the behaviour of the tumours during the three years following
irradiation. "Cured" implies a permanent local regression, irrespective of the
patient's general health or the presence of metastases; "recurred " implies a
temporary response of the tumour followed by recurrence within the treated
field; where no regression has occurred the tumour is classified as "persisting ";
and in two cases in the higher dosage range the treated area "necrosed," accom-
panied by local recurrence.
For the purpose of correlating the probability of cure with dosage, the 100
cases were divided, in order of increasing dosage, into the five equal groups shown
in TableIII. The average dose received by each group was determined (on
account of some outlying values the median dose was taken in preference to the
mean), and the number of cured cases in the group was counted. In Fig. 3 each
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TABLE III.-Results of Treatment.
Site.
Face
Orbit
Neck node
Larynx
Back
Tongue
Pharynx
Neck
Nosoe
Alveolus
Neck
Face
Scalp
Larynx
Tongue, base
Pharynx
Orbit
Face
Temple · Post-cricoid
. Alveolus .
. Face
Penis
. Scalp
Epiglottis
Tonsil
. Face
Larynx
Epiglottis
. Ear, pinna
Pharynx .
Nasopharynx
Nose
Ear, pinna
Scalp
Lip .
. Tonsil
Ear, pinna
Lip .
Scalp
. Face
Larynx
Cheek, oral
Scalp
Hand, dorsum
.Face
Penis
Scalp
Lip .
Tongue
Neck nodes
Nose
Hand, dorsum
Field
(cm.).
5 0
7X7
15 x 15
90
8X6
30
10x8
8X6
10x10
3 0
3 O
80
8X20
8 O 15xO10
4 0
8 0
15 x 10
4 0
7X7
3 0
4X4
15X6
6x6
8X5
14 0
10x8
8x6
30
7x7
8X6
8 O
15xl10
18x10
4x4
2 0
12 x 12
5 0
10x10
2X2
8x6
2
2 0
40
30
3 O
8x6
10 x 10
40
30
4x4
3 O
7x7
7x7
7x7
x
18x10
3 0
6X6
RBE*.
0107
0-7
0 6 0156
066
015
· 0.7
0-6
.0-6
0* 5
0.5
0- 5
0*5
0* 5
0-5
. 0.5,
0*5
0. 6
0-6
1.0
06
0.5
0-5
0.6
0.5
0.5
0-7
0.5
0-6
0.6
0.5
0-6
0-6
0.5
0-6
0-6
0·7
0·5
0-5
0-5
0.6
1.0
0.5
0.5
0.5
0.5
0.5
0.5
06
0.5
0.5
05
0.5
0.5
05
057
0.6
1.0
06
0.6
0.5
0.5
Dose*
(r).
3200
2300
2250
3300
3150 · 2000
3800
3500
3000 · 1400
2000 · 3000 · 3150
3000
3300
4400
3600
5000 · 3750 · 2250
3300
. 4600 · 3700
3000
4200
3300
4600
. 4300
1600
4200
4300
3350
. 4000
. 4000
5000
2190
3450
3800
. 4100
3300
. 3600
2000
2000
2550
1700
1700
4500
3300
4000
2700
1800
3400 · 3400
3650 · 4600 · 7700 · 4800
4500
3350
3400
Time Rec.* Result. (days).
60 . 1630 . Recurred
7 .1730 . 9
12 . 2010 . Persists
40 .2180 . ,,
32 .2210 . ,,
10 . 2250 .
45 . 2430 Recurrec
23 .2650 . ,,
21 . 2800 . ,
1 . 2800 . Persists
4 . 2830 . Recurrec
18 . 2900 . Persists
22 .2900 . ,
18 . 2900 . Recurrec
. 26 .2900.
40 . 2940 . Cured
17 . 2950 . Persists
8 .2960.
19 . 2990 . Cured
5 . 3000 . Persists
22 . 3050 . Recurrec
40 . 3060 . Cured
33 . 3090 . Recurrec
14 . 3100.
14 . 3100 . Cured
20 . 3110 Recurre(
36 .3140 . ,,
26 .3140.
1 .3200. Cured
23 .3200 . ,,
26 . 3200 .
18 . 3250 . Recurre(
18, . 3250 . Cured
18 .3250 . ,,
23 .3250 . ,,
3 .3260. ,,
20 .3270.
. 28 . 3300 . Recurre(
18 .3300
1 .3300. Cured
22 . 3330 . Recurrec
2 .3350. Cured
2 .3350. ,,
5 .3400. ,,
1 .3400 . ,,
1 .3400 . ,,
23 .3420 . ,,
13 .3480 . ,,
25 .3560 . ,,
5 .3600. ,,
1 .3600 . ,,
13 .3600 . ,,
12 .3620 .
4 . 3630 . Recurrec
20 . 3630 . Cured
20 .3640.
23 . 3650 . Recurrec
18 . 3650 . Cured
11 .3700 . ,,
11 .3750 . ,,
I'
t
d
d
d
d
d
I
d
I1
i
i
J
Median Percentag(
dose. cured.
2815 { 2/20
=10%
3200 { 11/20
=55%3600 { ~~~~1/2
3600 172
1 ~=85%
Case
No.
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
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TABLE III.-cont.
Site
Neck
Lip
Nose
Ear, back.
Nose
Face
Branchial .
Alveolus
Ear, pinna
Hand, dorsum
Face
Tongue, base
Lip
Neck node
Nose
Ear, pinna
Hand, dorsum
Tongue
Lip
.
Ear, pinna
Face
Lip
Larynx
Hand, dorsum
Neck
Face
Antrum
Ear, pinna
Temple
Face
Cheek
Face
Cheek
Face
Nose
Scalp
Forehead
Face
Field
(cm.).
30
40
40
40
50
30
30
10X8
7X7
4X3
40
30
7x7
4x4
6X6
7x7
30
20
4X4
5X5
40 5X2
30
50
4X4
80
30
50
60
80
30
30
2 0
3x2
4X4
30
30
80
30
2x2
RBE.*
Dose*
(r).
0* 0.5 . 3700
0-5 . 3500
0.5 . 3500
0-5 . 4000
0.5 . 3400
0-5 . 3000
0.5 . 2550
0- 6 .4500
0 6 . 5000
1-0 . 4000
1-0 . 6000
0-5 . 2000
0 6 . 5600
0-6 . 4500
1.0 . 6400
1-0 . 6500
0-5 4000
05 . 2100
05 4500
1.0 . 7000
0.5
0-5
0.5
0.5
0-6
0.5
0.5
0.5
1-0
0-5
0.5
0.5
0.5
1.0
0.5
0.5
0.5
0.5
0.5
0-5
4000
4100
3400
4200
9500
5000
4000
4250
8000
5200
4200
3800
2500
6000
5200
5100
6000
6000
6000
5100
Time Rec *
(days).
15 . 3750 .
12 . 3760 .
12 . 3760 .
20 . 3800 .
10 . 3810 .
6 .3840.
3 .3850.
13 . 3950 .
20 . 2980 .
1 .4000.
5 .4000.
1 .4000.
29 . 4000 .
12 . 4050 .
6 .4100.
6 .4150.
13 . 4200 .
1 .4200.
17 . 4300 .
7 .4300.
21
13
5
12
144
23
9
11
8
21
9
5
1
2
15
13
16
16
14
7
4300 .
4300 .
4500 .
4510 .
4550 .
4600 .
4600 .
4700 .
4750 .
4850 .
4850 .
5000 .
5000 .
5050 .
5200 .
5310 .
6000 .
6000 .
6200 .
6200 .
Result. Median Percentage dose. cured.
Cured
,,9
,,9
,,5 4000 { 19/20
ReCUrred
CUred
,,1
,,9
,,9
,,9
,,9
,,3
Cured
,,
Necrosed
Cured
Necrosed
Recurred
Cured
,,5
,,9
,,9
,,9
,,9
,,9
9,,
9,9
4850 { 17/20
4850 =85%
* RBE = "Reciprocal biologic efficiency" compared to v-rays as unity.
Dose = Minimum tumour dose, estimated for each case from isodoses.
Rec = "Roentgen equivalent clinical"; dose corrected for quality and time.
step represents one group of 20 cases. The horizontal extent of the step illus-
trates the range of dosage, while the vertical height indicates the percentage of
tumours cured in that group. The circles represent the median dose for each
group, and the smooth curve drawn through them is probably the true curability
curve for epidermoid cancer. It is of interest to note that in the highest dosage
range the curability is considerably less than expectation. This deviation is
associatedwiththe cases of "necrosis plus recurrence," and confirms theexistence
of the supralethal effect (Paterson, 1948).
In Fig. 4 the same data are charted on lognormal probability co-ordinates,
the ordinate representing the percentage cured. The straight line obtained
proves the almost perfect lognormality of the grouped data. The mean lethal
Case
NO.
211
212
213
214
215
216
217
218
219
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FIG. 3.-Cumulative frequency diagram illustrating increased proportion of tumours cured
with increasing biological dosage. Doses are expressed in roentgens equivalent clinical (rec).
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FIG'. 4.-Test for lognormality of the tumour dosage data. The outlying point on the right
illustrates the "supralethal effect." The inset demonstrates a method for determining
the recovery exponent (n).
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dose is seen to be about 3000 rec (in good agreement with previous estimates),
and the uncertainty factor is 1.3.
The inset in Fig. 4 illustrates a method for determining the recovery exponent
(n) by a graphical solution. Various values of n ranging from zero to 0.5 were
selected, and the resultant estimates of biological dose tabulated in a manner
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FIG. 5.-Nomogram relating skin tolerance and epidermoid cancer lethal doses with time
and volume factors. Doses apply to conventional 200 kV deep therapy. A single line
across the diagram gives all the relevant factors simultaneously.
similar to Table III but regrouped accordingly. The cure rates so obtained
were similarly charted in lognormal probability graphs, and the values of the
standard deviation factor (f) corresponding to each value of n was determined.
It is seen that fis a minimum as n approximates 0-25. The disadvantage ofthis
graphical method, which is otherwise simple and sufficiently accurate for practical
purposes, is that it furnishes no means for computing the variance of n. It is,
therefore, impossible to test the agreement between ourroughestimate ofn =0.25
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and similar data from other sources, e.g., Strandqvist's (1944) n = 0.22. How-
ever, Kerrich (Statistical Note) estimates this value to lie between 0-24 and 0.34,
with a mean of 0.29.
DISCUSSION.
Therapeutic Ratio.
The object of this investigation is to determine the optimum dose for the
treatment of epidermoid cancer. For this purpose it is necessary to deliver that
dose which will give the largest proportion of tumour regressions, and yet rarely
or never exceed the limits of skin tolerance. It has been shown that a standard
erythema reaction is given in the average case by 1000 rec, and in 95 per cent
ofcases the dose lies between ± 25 per cent ofthis value (that is, 800 to 1250 rec).
An erythema would be encountered in less than 2 per cent of cases receiving
750 rec or lower; and the same proportion of cases, therefore, might be expected
to develop necrosis with 3000 rec. Estimated on the basis of the iso-effect
formula, then 3000 rec can be accepted as the skin tolerance dose, with a risk of
necrosis ofunder 2 per cent.
The probability of curing an irradiated tumour increases with increasing
dosage up to a maximum of95per cent at a dose of4000 rec (Fig. 3), beyond which
the supralethal effect becomes increasingly menacing. It is, therefore, advisable
to exceed the mean lethal dose of 3000 rec whenever possible by a factor approach-
ing two standard deviations (30per cent), remaining, of course, within the bounds
ofthe skin tolerance.
The ratio of skin tolerance to mean lethal dose has been defined as the thera-
peutic ratio; and the writer has shown (Cohen, 1949) that this ratio can be
varied within wide limits by a judicious selection of field-size and over-all time.
It was pointed out that the therapeutic ratio must always be greater than unity
and, if the radiation is not absolutely homogeneous, should exceed the hetero-
geneity factor. When the therapeutic ratio equals 100, the skin tolerance dose
is identical to the mean tumour lethal dose, so that the MLD cannot be exceeded,
and a cure rate ofnot more than 50 per cent can be expected. It has been shown
that the maximum probability of cure is given by a tumour dose of 1.3 MLD's.
In general, therefore, the optimum combination of time and area is that which
gives a therapeutic ratio of not less than 1.3, in which case the probability of
cure may approach 95 per cent. The time and area factors corresponding to a
given therapeutic ratio can be determined from the author's nomogram (Cohen,
1949), of which a modified version is reproduced in Fig. 5.
It has been asserted that the prognosis is proportional to the therapeutic
ratio. Since the probability of cure is dependent both on this ratio and on the
variance of the MLD, the statement can be expressed quantitatively in the form
0 log
0 = H.fc or c - log f' ' ~~~log f'
where 0 is the therapeutic ratio obtaining with a given combination of field-size
and treatment time, H is the heterogeneity factor, equal to the ratio of the
maximum tissue dose to the minimum tumour dose, and f is the standard devia-
tion factor, equal to 1.15 for our data.
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It is then possible to calculate c the normal deviate, with which is associated
a definite probability. The probability of cure, corresponding to any given
value ofc, canbe determined from statisticaltables or from theordinates ofFig. 4.
It will be noted that c = 0 corresponds to a cure rate of 50 per cent; c = 1 to
85 per cent; and c = 2 to 97.5 per cent. In this way a definite prognosis, as far
as the primary growth is concerned, can be assigned to any epithelioma ofknown
size treated, over a given number of days, to the limits of skin tolerance.
SUMMARY.
A statistical analysis ofthe intensity ofthe skin reaction in 150 cases, and its
dependence on the time (T), field-size (L), and the biological efficacy (a) of the
radiation used, confirmed the general validity of the simplified "iso-effect"
formula D = E.a. (). By means of the method of least squares, estimates
of a and n for six different qualities of radiation were obtained, and shown to be
in good agreement with previously established data. The uncertainty factor in
dosage estimated on this basis ranged from 1.21 to 1-35.
A further 100 cases of epidermoid cancer were similarly analysed in order to
determine the dependence of curability on the biological dose. The median
lethal dose for this tumour (3000 rec) and its uncertainty factor (1.3) were deter-
mined, and it was shown that, under optimal conditions of time and area, 95 per
cent of tumours could be cured with a dose exceeding the median lethal dose by
30 per cent. It has also been demonstrated that the prognosis is a mathematical
function ofthe therapeutic ratio.
The author wishes to acknowledge the valuable advice given by Mr. J. E.
Kerrich, Department of Mathematics, University of the Witwatersrand, and his
generous assistance with the statistical portion of this work. In particular he
has examined the graphical method for determining the recovery exponent (n)
for epidermoid cancer, and considers the operation mathematically legitimate and
reasonably accurate.
STATISTICAL NOTE BY J. E. KERRICH.
From the data in Table III Dr. Cohen suggests that biological dose = dose/
RBE x Tn, or X = Z/Tn say, where X- biological dose, Z- dose/RBE,
T = time in days. He goes on to show that if X is the exact dose necessary to
effect a cure, then a reasonable assumption is that log X = log Z - n log T is
normally distributed.
Writing x = log X, z = log Z, t = log T this hypothesis becomes x = z - nt
is normally distributed with, say, mean oc and variance a2.
By a neat graphical method he proceeds to estimate ac, n and a. The dis-
advantage of his method is that it affords no clue as to the reliability of his esti-
mates. To study this question ofreliability we must employ analgebraic method.
The author's problem is, in principle, reminiscent of a problem examined in D. J.
Finney's Probit Analysis (p. 106, Ex. 18), and adapting the algebraic methods
explained in Appendix II of that book, the following results were obtained
(omitting cases 236 and 240):
c n
Estimated value . . . 34642 . . 2893 . -0709
Estimated standard deviation -0359 . 0285 . 0186
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The sizes ofthe estimated standard deviations show that none ofthe constants
can claim to be very "well determined." It must, however, be remembered
that we are not dealing with a planned experiment, but that the author had to
use the data that were to hand. As a suggestion to future workers in this field,
more observations for small values of t (say t 0) and large values of t (say
t -1.5) would help greatly in fixing c and n more accurately.
In more detail, the estimated covariance matrix is
var. (oc) - 001292 coy (oc, n) = - 000955 coy (oc, a) = - 000383
var (n) -+ -000813 coy (n, a) - + -000227
var (a) = -000348
The mean value of x is oc. We estimate that this lies between 3.4642 i .0718
with 5 per cent risk. This makes our estimate of median X to be 2912 rec with
a 5 per cent uncertainty factor of 1.180.
Ifx is greater than oc + 2a, then the cure rate should be 97.5 per cent or more.
Our estimate of oc + 2a is 3.6060 i .0679, and the corresponding biological
dose is X = 4036 rec with a 5 per cent uncertainty factor of 1.169.
Our thanks are due to the computing staff of the National Institute of Per-
sonnel Research for their help in preparing this note.
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